货号：DT2025060779
CAS：1346603-30-2
规格：mg(更多包装需求请咨询客服)
纯度：≥98%
生产商：试剂家

生物活性：Nefopam-d3 (hydrochloride) is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Nefopam-d3 hydrochloride 相关抗体:
Beta-Catenin Antibody
TCF7L2/TCF4 Antibody
beta Catenin Antibody (YA936)
beta Catenin Antibody (YA938)
Phospho-delta 1 Catenin (Ser268) Antibody (YA1019)
Phospho-beta Catenin (Ser33/Ser37) Antibody (YA3096)
gamma Catenin Antibody
beta Catenin Antibody (YA937)
Phospho-delta 1 Catenin (Tyr228) Antibody (YA1018)
Phospho-delta 1 Catenin (Thr916) Antibody (YA1020)
分子量：292.82
Formula：C17H17D3ClNO
CAS 号：1346603-30-2
非标记 CAS：23327-57-3
性状：固体
颜色：White to off-white
中文名称：盐酸奈福泮 d3 盐酸盐
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Powder：-20°C：3 years，4°C：2 years
In solvent：-80°C：6 months，-20°C：1 month
纯度 & 产品资料
纯度： ≥98.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11.
 [Content Brief]
[3]. Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36.
 [Content Brief]
[4]. Poon R, et al. A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One. 2012;7(5):e37940.
 [Content Brief]